Cagrilintide Research: What is Cagrilintide? How does it work?
The Obesity Epidemic
Obesity has become one of the most pressing public health challenges in the United States and around the world. In the U.S., about 42% of adults are classified as obese, a figure that has nearly tripled over the past 50 years. Globally, over 650 million people are classified as obese, and this number continues to rise rapidly. Obesity increases the risk for many serious health conditions, including heart disease, type 2 diabetes, stroke, and certain cancers, making it a major contributor to premature death and disability worldwide.
Obesity is difficult to control due to several complex factors. It’s not simply a matter of overeating or lack of exercise; rather, it stems from a mix of genetics, hormonal imbalances, metabolism, and environmental factors, such as the easy availability of high-calorie foods and increasingly sedentary lifestyles. This complexity makes it challenging to address basic "eat less, move more" strategies. Additionally, many individuals struggle with yo-yo dieting, where initial weight loss is followed by weight regain once normal eating patterns resume. This cycle makes maintaining weight loss over the long term even more difficult. Furthermore, the medications currently available for weight loss often have limited effectiveness and can come with side effects, making them less appealing for long-term use. Most of these drugs only target specific aspects of obesity, like appetite suppression or metabolism, which doesn't fully address the root causes of the issue.
How Research with Cargrilintide Can Offer Hope
Cagrilintide, a long-acting analogue of the hormone amylin, presents a promising new approach to tackling obesity. Here’s how it could help solve this issue:
1. Multi-Action Approach: Unlike many weight-loss drugs that only target one mechanism, cagrilintide works on multiple fronts. It suppresses appetite by promoting feelings of fullness (satiety) and slows down gastric emptying, making people feel full for longer periods of time. By reducing overall calorie intake, it helps people stick to lower-calorie diets more effectively.
2. Sustained Weight Loss: Early trials of cagrilintide have shown that it leads to significant weight loss compared to placebo and even other peptides like liraglutide, which is currently used for obesity treatment. In one study, participants taking cagrilintide lost up to 10.8% of their body weight over 26 weeks, outperforming those on liraglutide. Sustained weight loss like this can help break the cycle of yo-yo dieting. I explain this exact study at the bottom of this article.
3. Combination Potential: Cagrilintide also shows promise when used in combination with other weight-loss options, such as semaglutide, which targets different aspects of appetite regulation. This multi-pronged approach can lead to even more effective and sustained weight loss by addressing different parts of the body’s metabolic pathways.
4. Tolerability: One of the biggest challenges with weight-loss peptides is that some can come with unpleasant side effects, particularly gastrointestinal issues. While some participants in cagrilintide trials experienced side effects like nausea, it was generally well tolerated, and many of the side effects diminished over time.
So, what is it?
Cagrilintide is a long-acting analogue of amylin, a hormone naturally produced by the pancreas that plays a crucial role in regulating feelings of satiety (fullness) and controlling food intake.
Understanding Amylin
Amylin is secreted along with insulin after eating and helps slow down the emptying of the stomach, suppresses glucagon secretion (a hormone that raises blood glucose levels), and sends signals to the brain that induce the feeling of fullness. Together, these actions help to regulate blood sugar levels and control appetite, particularly by reducing the desire to continue eating after a meal.
This image illustrates the functions of amylin, a hormone secreted by the pancreas alongside insulin. Amylin plays a critical role in regulating several physiological processes, particularly those related to metabolism, appetite, and blood sugar control. Here's a breakdown of the diagram:
Key Functions of Amylin:
1. Reduction in Food Intake and Satiety Signaling:
○ Amylin decreases food intake by promoting feelings of fullness. It works in conjunction with other hormones like leptin and peptide YY to signal the brain that the body is full, reducing appetite.
2. Slowing Gastric Emptying:
○ Amylin slows down the rate at which food moves from the stomach into the intestines. This helps prevent blood sugar spikes by allowing more time for nutrients to be absorbed and for insulin to work more effectively. This also contributes to feeling full for a longer period.
3. Body Weight Regulation:
○ By reducing food intake and slowing gastric emptying, amylin indirectly helps in reducing body weight.
4. Interaction with Insulin and Glucagon:
○ Amylin complements insulin by reducing the release of glucagon, a hormone that raises blood sugar levels. This ensures better overall blood sugar control.
5. Effects on Bone Health:
○ Amylin also influences bone metabolism by reducing osteoclast activity (cells that break down bone) and increasing osteoblast activity (cells that build bone). This promotes stronger bones and enhances bone formation.
6. Vasodilation:
○ Amylin can increase vasodilation, which is the widening of blood vessels. This effect helps regulate blood pressure and improve circulation.
7. Renin Activity:
○ Amylin plays a role in reducing renin activity, which is part of a system that regulates blood pressure. By lowering renin levels, it may help with managing blood pressure.
In summary, amylin regulates appetite, controls blood sugar levels, supports bone health, and affects blood pressure. Its multifunctional nature makes it a key player in metabolic regulation, and its analogues (like cagrilintide) are being developed for weight management therapies due to these effects.
How Cagrilintide Works
Cagrilintide mimics the natural effects of amylin but is designed to have a longer duration of action. Like amylin, it acts on areas of the brain involved in hunger and satiety, particularly the hypothalamus. By reducing appetite and promoting satiety, cagrilintide can lead to reduced calorie intake, ultimately contributing to weight loss.
Why Cagrilintide is Important
One of the main challenges with using natural amylin as a treatment is its rapid breakdown in the body. Amylin, a hormone co-secreted with insulin, is unstable and degrades quickly, limiting its therapeutic utility. To address this, researchers developed cagrilintide, a synthetic analogue of amylin designed to be more stable and long-lasting in the body.
Cagrilintide's molecular structure has been modified to resist the enzymatic processes that typically break down natural amylin. As a result, it has a longer half-life, allowing it to remain active in the body for a more extended period. This feature is a significant advantage, as it enables patients to take it less frequently—typically once a week—which enhances its practicality for long-term use. Many weight-management medications need to be administered daily, which can be cumbersome and lead to poor patient adherence. The once-weekly dosing of cagrilintide could help improve patient compliance, making it easier for individuals to stick to their treatment plans.
The longer duration of action not only makes it more convenient but also allows cagrilintide to continuously regulate appetite and promote satiety throughout the week. This steady effect helps reduce daily calorie intake without needing constant drug administration, making it an attractive option for both clinicians and patients looking for effective long-term weight management solutions. In this way, cagrilintide offers a more practical and patient-friendly alternative to amylin in the battle against obesity.
Clinical Use and Research
Cagrilintide is currently being studied in clinical trials as a potential treatment for overweight and obesity. The aim is to help individuals lose weight by reducing appetite and controlling food intake. Early studies, such as the one summarized earlier, have shown promising results, with patients experiencing significant weight loss compared to placebo and even compared to other weight-loss drugs like liraglutide.
Combination Therapies
There is also research exploring combination therapies, where cagrilintide is used together with other weight management drugs like semaglutide (another peptide that targets the brain's hunger centers). The combination may provide more effective and sustained weight loss results by addressing multiple pathways in the body’s appetite regulation system.
Summary of Clinical Trial (Research only) using Cargrilintide:
Example 1:
Background: Amylin, a natural hormone produced by the pancreas, promotes feelings of fullness. Cagrilintide, a long-lasting amylin analogue, is being studied for its potential in weight management. This study explored the relationship between cagrilintide doses and its effects on body weight, safety, and tolerability.
Methods: A phase 2, multicenter, randomized, double-blind trial was conducted across 57 sites in 10 countries, including Canada, Japan, and the USA. The study enrolled adults aged 18 or older, without diabetes, but with a body mass index (BMI) of at least 30 kg/m² or 27 kg/m² if they had hypertension or dyslipidemia. Participants were assigned to receive weekly self-injections of cagrilintide (at doses from 0.3 mg to 4.5 mg), daily liraglutide (3.0 mg), or placebo. The trial lasted for 26 weeks, including a 6-week dose-escalation period and a 6-week follow-up without treatment. The primary goal was to measure the percentage change in body weight from the start to week 26. Safety data was collected from all participants who received at least one dose of treatment.
Findings: From March to August 2019, 706 participants were randomized into groups receiving cagrilintide (100-102 per dose), liraglutide (99), or placebo (101). About 10% of participants discontinued treatment, mostly due to side effects (4%). On average, participants who received cagrilintide lost more weight (6.0% to 10.8% body weight reduction) compared to placebo (3.0%). At the highest dose, cagrilintide resulted in more weight loss compared to liraglutide (10.8% vs. 9.0%, p=0.03). Gastrointestinal side effects, like nausea, were the most common adverse events, occurring more frequently in the cagrilintide groups compared to placebo.
Interpretation: Cagrilintide treatment in individuals with overweight and obesity led to significant weight loss and was generally well tolerated. These results support further development of new treatments with innovative mechanisms for managing weight.
Example 2:
Researchers have previously demonstrated that combining amylin and leptin agonists results in a synergistic weight loss effect in rats with diet-induced obesity (DIO). In this study, we evaluated how well amylin, leptin, or their combination maintained the weight loss induced by this combination. DIO rats were initially treated with a combination of rat amylin (50 µg/kg/day) and murine leptin (125 µg/kg/day) for 4 weeks. Following this, the rats received either a placebo (vehicle), amylin, leptin, or the amylin + leptin combination for an additional 4 weeks. We measured food intake, body weight, body composition, plasma biomarkers, and the expression of key metabolic genes in the liver and white adipose tissue (WAT).
During the first 4 weeks, the amylin + leptin treatment reduced body weight to 87.5% of baseline. After switching treatments, rats receiving placebo or leptin regained all their lost weight (104.2% and 101.2% of baseline, respectively), while those on amylin alone had partial weight regain (97.0%). In contrast, rats that continued receiving both amylin and leptin maintained much of their weight loss, stabilizing at 91.4% of baseline, with a 10% reduction in body fat. Over the course of the final 4 weeks, food intake was reduced in rats treated with amylin and the combination, but not by leptin alone. The amylin + leptin combination also significantly lowered plasma triglycerides (by 55%), total cholesterol (by 19%), and insulin levels (by 57%) compared to placebo.
On a molecular level, amylin + leptin reduced hepatic Scd1 mRNA and increased adiponectin, Fasn, and Lpl mRNA levels in WAT. These findings suggest that in DIO rats, sustained weight loss requires ongoing treatment with both amylin and leptin and is linked to improved body composition, lipid metabolism, and insulin sensitivity.
Conclusion
Cagrilintide represents a novel approach to managing obesity and overweight by leveraging the body’s natural mechanisms for regulating appetite and food intake. By mimicking the effects of amylin but with a longer duration of action, it offers a promising new option for individuals seeking long-term weight loss solutions. Ongoing research studies will help determine its long-term safety and effectiveness as part of comprehensive weight management strategies.
References:
